Skip to main
VNRX

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX Ltd has achieved its first revenue from CE-Marked Nu.Q NETs automated assay sales and has expanded evaluations to over 20 hospitals across 10 countries, indicating solid traction in the market. The company has formed strategic licensing agreements with established leaders such as Werfen and Hologic, enhancing its commercial infrastructure and potential for broader diagnostics deployment. Additionally, VolitionRX's innovative low-cost blood-based workflow and ongoing scientific advancements serve to strengthen the commercial viability and clinical appeal of its Nucleosomics platform, positioning the company favorably for future growth in human and veterinary diagnostics.

Bears say

VolitionRX Ltd faces an increased dilution risk, contributing to a negative financial outlook for the company. This heightened risk is reflected in a revised price target reduction from $5.0 to $3.0, signaling potential challenges in maintaining shareholder value. The implications of these financial adjustments underscore concerns regarding the company's ability to effectively capitalize on its Nucleosomics platform for growth amidst such risks.

Volitionrx Limited (VNRX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Jan 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.